Safety and Tolerability of Combinations of Empagliflozin/Linagliptin (EMPA/LINA) for 52 Weeks in Subjects with Type 2 Diabetes (T2DM)

被引：0

|

作者：

Patel, Sanjay

Defronzo, Ralph A.

Lewin, Andrew

Liu, Dacheng

Kaste, Renee

Kohler, Sven

Woerle, Hans J.

Broedl, Uli C.

机构：

来源：

DIABETES | 2015年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1259-P

引用

收藏

页码：A326 / A327

页数：2

相关论文

共 50 条

[41] Linagliptin (LINA) as Add-on to Empaglifl ozin (EMPA) and Metformin in Patients with Type 2 Diabetes (T2DM): Two 24-Week Randomized, Double-Blind, Parallel-Group Trials
Tinahones, Francisco J.
Gallwitz, Baptist
Nordaby, Matias
Goetz, Sophia
Maldonado, Mario
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2016, 65 : A50 - A50
[42] NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY OF EMPAGLIFLOZIN MONOTHERAPY OVER 24, 52, AND 76 WEEKS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Daacke, I
Batson, S.
Burton, H. E.
Tebboth, A.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A667 - A667
[43] A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes
Gallwitz, Baptist
[J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (12) : 1399 - 1405
[44] HbA1c Response to Open-Label (OL) Empagliflozin (EMPA) with Metformin (MET) in Patients with Type 2 Diabetes (T2DM)
Schernthaner, Guntram
Tinahones, Francisco J.
Goetz, Sophia
Lee, Christopher
[J]. DIABETES, 2017, 66 : A345 - A346
[45] Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
Kim, Esther S.
Deeks, Emma D.
[J]. DRUGS, 2015, 75 (13) : 1547 - 1557
[46] Type 2 diabetes: Trajenta® (linagliptin) and empagliflozin
Coquard-Schmidt, Barbara
[J]. CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2012, 16 (09): : 279 - 279
[47] Empagliflozin as Add-on to Linagliptin and Metformin in Patients with Type 2 Diabetes (T2DM): Subgroup Analysis by Region in a 24-Week Randomized Trial
Wanner, Christoph
Naderali, Ebrahim
Maldonaldo, Mario
Del Parigi, Angelo
Toorawa, Robert
Lee, Christopher
[J]. DIABETES, 2016, 65 : A288 - A289
[48] Safety and tolerability of colesevelam HCl in patients with T2DM
Schwartz, Sherwyn L.
Zieve, Franklin
Kalin, Marcia
Jones, Michael R.
[J]. DIABETES, 2006, 55 : A480 - A480
[49] Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
Esther S. Kim
Emma D. Deeks
[J]. Drugs, 2015, 75 : 1547 - 1557
[50] Diuresis-related Safety and Tolerability of Dapagliflozin (DAPA) in T2DM Over 24 Weeks
Johnsson, Kristina M.
Johnsson, Eva
Mansfield, Traci A.
Apanovitch, Anne Marie
Ptaszynska, Agata
Yavin, Yshai
Parikh, Shamik J.
List, James F.
[J]. DIABETES, 2014, 63 : A265 - A266

← 1 2 3 4 5 →